期刊文献+

扶正固本Ⅰ号方对晚期非小细胞肺癌患者免疫功能及生活质量的影响 被引量:12

Effects of "Fuzheng Guben Decoction" on immune function and quality of life in advanced non-small cell lung cancer patients
下载PDF
导出
摘要 目的观察中药扶正固本Ⅰ号方对晚期非小细胞肺癌(NSCLC)患者免疫功能及生活质量(QOL)的影响。方法将107例Ⅲ、Ⅳ期NSCLC患者随机分为化疗组(对照组)53例、化疗+中药组(治疗组)54例,分别给予单纯化疗和化疗结合扶正固本Ⅰ号方治疗。4个周期后,观察患者T细胞亚群、KPS评分、化疗毒副反应情况;SF-36调查表评估患者生活质量。结果治疗组治疗后CD3较治疗前明显提高(P<0.05),而对照组CD3、CD4化疗后较化疗前明显降低(P<0.05),治疗后治疗组CD4/CD8较对照组有明显提高(P<0.05);治疗组生活质量改善优于对照组(P<0.05);治疗组KPS评分稳定率高于对照组(P<0.05);对照组骨髓抑制较治疗组严重(P<0.05)。结论扶正固本Ⅰ号方能提高晚期NSCLC患者的免疫功能,改善生活质量,减轻化疗的毒副反应。 Objective To observe the effects of "Fuzheng Guben Decoction" on immune function and quality of life(QOL) in phase-Ⅲ and Ⅳ non-small cell lung cancer(NSCLC).Methods One hundred and seven patients with phase-Ⅲ and Ⅳ NSCLC were randomized into two groups:control group in which 53 cases were treated by chemotherapy only and treatment group in which 54 cases were treated by combined chemotherapy and "Fuzheng Guben Decoction".After 4 cycles,the T cell subsets,KPS score and chemotherapeutic side effects were observed;SF-36 questionnaire was used to assess the quality of life.Results After treatment,the content of CD3 was increased in the treatment group(P0.05),the contents of CD3 and CD4 were lowered in the control group(P0.05),the CD4/CD8 was higher in the treatment group than in the control group(P0.05);the quality of life was higher in the treatment group than in the control group(P 0.05);the KPS score was higher in the treatment group than in the control group(P0.05);the bone marrow suppression was more severe in the control group than in the treatment group(P0.05).Conclusion "Fuzheng Guben Decoction" can enhance advanced NSCLC patients’ immune function,improve quality of life and relieve chemotherapeutic side effects.
出处 《上海中医药杂志》 2010年第12期37-39,共3页 Shanghai Journal of Traditional Chinese Medicine
基金 上海市青浦区自然基金资助项目(2004-44)
关键词 非小细胞肺癌 扶正固本Ⅰ号方 免疫功能 生活质量 Non-small cell lung cancer "Fuzheng Guben Decoction" immune function quality of life
  • 相关文献

参考文献13

  • 1Byrne B,Crawford J,Gay G,et al. Trends in chemotherapy use and sur- vival for patients with metastatic non-small cell lung cancer [ J ].Journal of Clinical Oncology ,2004,22 ( 14 ) :7072.
  • 2Rajappa S, Gundeti S, Talluri MR, et al. Chemotherapy for advanced lung cancer : A 5-year experience [ J ]. Indian Journal of Cancer, 2008, 45(1 ) :20-26.
  • 3周建伟 朱斌 石建国.扶正中药对恶性肿瘤化疗患者的疗效及生活质量影响的临床研究.中华肿瘤防治杂志,2007,14(15):45-48.
  • 4中华人民共和国卫生部医政司.常见恶性肿瘤诊治规范[M].北京:中国协和医科大学出版社,1999.773-781.
  • 5Moutain CF. Revisions in the international system for staging lung cancer [J]. Chest,1997,111 (6) :1710-1717.
  • 6吴一龙.局部晚期非小细胞肺癌.肺癌杂志,2002,2(13):21-21.
  • 7Rivera MP. Multimodality therapy in the treatment of lung cancer [ J ]. Semin Respir Crit Care Med,200g ,25 (Suppl 1 ) :3-10.
  • 8王笑民,辛海,杨中,赵文硕,杨国旺,刘炬,唐武军,张青,韩冬,郁仁存.固本消瘤胶囊治疗晚期非小细胞肺癌的临床研究[J].中国中西医结合杂志,2004,24(11):986-988. 被引量:21
  • 9林丽珠,周岱翰,郑心婷.中医药提高晚期非小细胞肺癌患者生存质量的临床观察[J].中国中西医结合杂志,2006,26(5):389-393. 被引量:78
  • 10Lukaszewicz M,Mroczko B, Szmitkski M. Clinical significance of inter leukin-6 (IL-6) as a prognostic factor of cancer disease [ J]. Pol Arch Med Wewn ,2007,117 ( 5-6 ) :247-251.

二级参考文献29

  • 1马凌娣,文世宏,张彦,何於娟,刘小珊,康格非,蒋纪恺.苦参碱对H_(22)荷瘤小鼠的抑瘤作用及对免疫功能的影响[J].中草药,2004,35(12):1374-1377. 被引量:15
  • 2王笑民,郁仁存,王禹堂,饶燮卿,彭晓梅,吉慧敏,冯灵娟.晚期非小细胞肺癌患者气虚血瘀证的研究[J].中国中西医结合杂志,1994,14(12):724-726. 被引量:56
  • 3马凌娣,张彦,文世宏,何於娟,刘小珊,康格非,蒋纪恺.苦参碱对荷瘤小鼠抑瘤作用的实验研究[J].中华肿瘤杂志,2005,27(6):339-341. 被引量:40
  • 4毛慧生,刘洪■,李川,宋燕爽,孙慧,冯玉梅,苏明秀.苦参碱对肿瘤细胞恶性表型及免疫功能的调控作用[J].中国肿瘤临床,1996,23(11):799-803. 被引量:59
  • 5沈关心 周汝麟.现代免疫学实验技术[M].武汉:湖北科学技术出版社,2002..
  • 6中华人民共和国卫生部医政司编.常见恶性肿瘤诊治规范.北京:中国协和医科大学出版社,1999:773-781.
  • 7Mountain CF.Revisions in the international system for staging lung cancer.Chest 1997; 111 (6):1710-1717.
  • 8Johnson JR,Temple R.Food and Drug Administration requirements for approval of new anti-cancer drugs.Cancer Treat Rep 1985 ;69(10):1155-1159.
  • 9Anderson H,Hopwood P,Stephens RJ,et al.Gemcitabine plus best supportive care (BSC) vs BSC in inoperable nonsmall cell lung cancer-a randomized trial with quality of life as the primary outcome.Br J Cancer 2000;83 (4):447-453.
  • 10Cardenal F,Lopez-Cabrerizo MP,Anton A,et al.Randomized phase Ⅲ study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer.J Clin Oncol 1999;17(1):12-18.

共引文献147

同被引文献172

引证文献12

二级引证文献121

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部